Immix Biopharma, Inc.
NASDAQ:IMMX · NASDAQ Capital Market
+$0.09 today
Vol 5.28M · Avg 1.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-31.4%
avg -62.2%
ROIC
-28.7%
avg -66.9%
ROA
-28.1%
avg -100.7%
Analysis
ROA is currently the strongest return metric at -28.1% versus its period average of -100.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ilya Rachman | Co-Founder, CEO, Chief Scientific Officer & Chairman | $760,000.00 | — | 53 | $500,000.00 | 0.92% |
Gabriel Morris | President, CFO & Director | $760,000.00 | — | 39 | $500,000.00 | 0.92% |
Graham Ross FFPM | Chief Medical Officer & Head of Clinical Development | $88,593.00 | — | 66 | $0.00 | <0.01% |
Vladimir Torchilin | Scientific Co-Founder | — | — | 79 | $905,200.00 | 1.66% |
David Marks | Chief Medical Officer of Cell Therapy | — | — | — | — | — |
Mel Davis-Pickett | Head of CMC Technical Development | — | — | — | — | — |
Michael A. Grabow | Chief Commercial Officer | — | — | — | — | — |
Sean Senn | Co-Founder | — | — | — | $899,800.00 | 1.65% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$20,214.42
Sells
0
$0.00
Net Sentiment
+$20,214.42
Net buying
Most Active
Rachman Ilya M
2 transactions
Analysis
Insiders reported 4 buys worth $20,214.42 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $20,214.42. Rachman Ilya M was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$260.02M
MacroGenics, Inc.
NASDAQ:MGNX
$256.48M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$209.65M
Surrozen, Inc.
NASDAQ:SRZN
$171.24M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.59M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$95.99M
Coya Therapeutics, Inc.
NASDAQ:COYA
$88.70M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$71.21M
Instil Bio, Inc.
NASDAQ:TIL
$51.41M
Atossa Therapeutics, Inc.
ATOS
$16.84M
Who manages IMMX?
Immix Biopharma, Inc. (IMMX) lists 8 active executives. The top listed executive is Ilya Rachman, Co-Founder, CEO, Chief Scientific Officer & Chairman.
Are IMMX insiders buying or selling?
Recent insider activity shows net buying of $20.44M.
Explore More
Continue the stock analysis
Jump to another research area for this company.